The research progress of gastric cancer vaccines: a narrative review Authors: Haoran Wu, Fan Zhang, Qiangzu Shao, Zeping Huang Published: 2026 ABSTRACT AbstractBackground and ObjectiveGastric cancer (GC) vaccines are an important component of immunotherapy for GC. In recent years, continued advances in immunotherapy have driven substantial progress in vaccine development. This review summarizes and critically appraises recent developments in GC vaccine research, aiming to provide insights that may inform future vaccine design and development.MethodsA detailed narrative review of the recent literature was conducted to summarize the latest research progress on GC vaccines. The PubMed database was searched, with the most recent search completed on 31 December 2025.Key Content and FindingsThis review summarizes recent advances in GC vaccine research. We briefly classify and describe current vaccine platforms, with a particular focus on emerging nucleic acid vaccines and nanovaccines and on strategies to enhance their efficacy. We also discuss approaches to overcoming the immunosuppressive tumor microenvironment (TME), optimizing the vaccine development pipeline, and evaluating artificial intelligence (AI)-based epitope prediction tools.ConclusionsSubstantial opportunities remain to optimize the research and development of GC vaccines. With continued advances in immunology, molecular biology, and AI, together with large-scale population validation and cost-effective manufacturing, personalized vaccines and rational combination strategies are expected to accelerate the clinical translation of GC immunoprophylaxis and therapy, ultimately improving patient outcomes.Keywords: Gastric cancer (GC), tumor vaccine, immunotherapy Introduction Gastric cancer (GC) is the fifth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related death (1). Although chemotherapy, targeted therapy, and immunotherapy have improved systemic treatment, most patients are diagnosed at an advanced stage, with a median overall survival (mOS) of only approximately 8 months, and conventional treatments offer limited benefits (2). Immunotherapy has become one of the important therapeutic strategies for advanced GC. Among them, tumor vaccines, as a form of active immunotherapy, exert antitumor effects by stimulating host immune responses and exhibit favorable tolerability and low dose-limiting toxicity, making them a current research hotspot (3). Tumor vaccines can deliver tumor-associated antigens (TAAs) and activate immune cells to specifically eliminate tumor cells, enabling precise therapy. Their applications mainly include palliative treatment for advanced cancer, adjuvant therapy after surgery, and tumor prevention in high-risk populations (4). GC has a high incidence and poor prognosis at advanced stages, with limitations in conventional treatments. Meanwhile, GC expresses defined TAAs, providing a basis for targeted vaccine design (5). Furthermore, vaccines can overcome the immunosuppressive microenvironment by optimizing delivery systems, incorporating adjuvants, and implementing combination therapies, which is expected to compensate for the shortcomings of existing treatments. This review summarizes the recent advancements in the development of various GC vaccines and provides an in-depth discussion on how to overcome the impact of the immunosuppressive microenvironment on GC vaccines, how to optimize the design of existing vaccines, and how to more scientifically evaluate vaccine efficacy. We present this article in accordance with the Narrative Review reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-aw-2299/rc). Methods A comprehensive narrative review of the relevant literature is presented in this article. We incorporated relevant English articles available in the PubMed database as at 31 December 2025. Search terms included ((Gastric Neoplasms[MH] OR Gastric Cancer[TW] OR Stomach Cancer[TW] OR Gastric Carcinoma[TW] OR Gastric Adenocarcinoma[TW] OR Stomach Neoplasm*[TW]) AND (Cancer Vaccines[MH] OR Therapeutic Vaccines[TW] OR Peptide Vaccine[TW] OR mRNA Vaccine[TW] OR DNA Vaccine[TW] OR Dendritic Cell Vaccine[TW] OR Viral Vector Vaccine[TW])) AND (Therapeutic[TW] OR Immunotherapy[TW]) NOT (Prophylactic[TW] OR Helicobacter Pylori Vaccine[TW] OR Prevention[TW] OR Prophylaxis[TW]). We reviewed all research papers, systematic reviews, and meta-analyses. Exclusions included case reports, letters to the editor, short communications, editorials, articles not written in English, studies with low relevance to the present literature review, and older articles with limited academic value. The search strategy is summarized in Table 1. Table 1The search strategy summaryItemsSpecificationDate of searchThe first search was conducted on 18 December 2024. The second search was conducted on 9 May 2025. The last search was conducted on 31 December 2025Database searchedPubMedSearch terms used ((Gastric Neoplasms[MH] OR Gastric Cancer[TW] OR Stomach Cancer[TW] OR Gastric Carcinoma[TW] OR Gastric Adenocarcinoma[TW] OR Stomach Neoplasm*[TW]) AND (Cancer Vaccines[MH] OR Therapeutic Vaccines[TW] OR Peptide Vaccine[TW] OR mRNA Vaccine[TW] OR DNA Vaccine[TW] OR Dendritic Cell Vaccine[TW] OR Viral Vector Vaccine[TW])) AND (Therapeutic[TW] OR Immunotherapy[TW]) NOT (Prophylactic[TW] OR Helicobacter Pylori Vaccine[TW] OR Prevention[TW] OR Prophylaxis[TW])Timeframe2008–2025Inclusion and exclusion criteria Inclusion criteria: relevant research articles, systematic reviews, and meta-analysesExclusion criteria: case reports, letters to the editor, short communications, editorials, articles not written in English, studies with low relevance to the present literature review, and older articles with limited academic valueSelection process Four authors (Z.H., H.W., F.Z., Q.S.) independently screened data sources. Data analysis was conducted by one author (H.W.)MH, Medical Subject Headings; TW, Text Word. The search strategy summary MH, Medical Subject Headings; TW, Text Word. Results Helicobacter pylori (H. pylori) vaccine The presence of H. pylori is strongly associated with the development of GC Infection with H. pylori is closely associated with gastric carcinogenesis. First, the helical morphology and flagella of H. pylori enable the bacterium to colonize the highly acidic environment of the stomach. By producing urease, H. pylori hydrolyzes urea into ammonia, which neutralizes gastric acid, damages the gastric mucosal barrier and creates a niche that supports persistent colonization. Second, H. pylori virulence factors, particularly cytotoxin-associated gene A (CagA), can be translocated into gastric epithelial cells, where they activate multiple intracellular signaling pathways and drive a sequence of precancerous alterations, including non-atrophic gastritis, atrophic gastritis, intestinal metaplasia and dysplasia. Ultimately leading to the development of GC (6-9). Basic clinical evidence of H. pylori vaccine’s anti-GC effect H. pylori vaccines are designed to deliver defined antigenic components of the bacterium to the host immune system, resulting in their activation and the generation of pathogen-specific antibodies and memory cells and conferring protection against primary infection and reinfection (10). Animal experiments have shown that H. pylori vaccination can promote bacterial clearance and reduce the risk of abnormal epithelial proliferation and subsequent carcinogenesis (6). Early-phase, small-scale clinical studies have reported that vaccinated individuals exhibit substantially lower H. pylori infection rates and improved gastric mucosal pathology. Moreover, longitudinal observations indicate a tendency toward reduced GC incidence in vaccinated cohorts, supporting the potential of H. pylori vaccines as a preventive strategy against gastric malignancy (11,12). Progress in H. pylori vaccine development In current clinical practice, H. pylori infection is predominantly managed with combination antibiotic regimens. However, this treatment regimen is often accompanied by a high recurrence rate and can lead to H. pylori resistance (8). In this context, the development of H. pylori vaccines offers a promising strategy for both the prevention and adjunctive treatment of H. pylori infection (13). Third Military Medical University and Chongqing KangWei Biotechnology in China have developed an oral recombinant H. pylori vaccine. A randomized, double-blind, placebo-controlled phase 3 clinical trial enrolled 4,464 participants, of whom 4,403 (99%) completed the three-dose regimen and were included in the efficacy analysis. After 3 years of follow-up, the vaccine demonstrated an efficacy of 71.8% (95% CI: 48.2–85.6%) against H. pylori infection (14). In an experimental study, Chehelgerdi et al. developed a DNA vaccine: pcDNA3.1(+)-cagW-CS-NPs. Mice vaccinated with pcDNA3.1(+)-cagW-CS-NPs showed marked protection against H. pylori infection at day 45 post-immunization (P<0.001) (15). Accumulating evidence indicates that Salmonella can serve as an efficient live vector for delivering heterologous antigens from diverse pathogens (16). Using this approach, Ghasemi et al. applied a novel Protective Immunity Enhanced Salmonella Vaccine (PIESV) platform. In their study, sterile protection against H. pylori SS1 infection was achieved in 7 of 10 immunized mice, highlighting the strong protective potential of this multicomponent vaccine (17). In parallel, Ni et al. constructed two oral live-carrier vaccines, named LL-UreA and LL-LTB-UreA. Oral vaccination with LL-UreA or LL-LTB-UreA markedly enhanced the production of interferon-gamma (IFN-γ), interleukin (IL)-17A and IL-10, and increased the count of CD4+IFN-γ+ and CD4+IL-17A+ T cells. Notably, administration of LL-UreA led to an approximate 70% reduction in H. pylori colonization in mice, underscoring the promise of live bacterial vectors for H. pylori vaccine development (18). More and more evidence indicates that H. pylori-induced cellular immune responses may, under certain conditions, exert inhibitory effects on tumor development (19). In one experimental study, fragments of the H. pylori virulence genes cagA, vacA and babA were cloned into a recombinant pcDNA3 plasmid, which was used to immunize BALB/c mice. Activated splenic CD3+ T cells were then purified from immunized animals. These CD3+ T cells significantly inhibited GC cell growth in vitro, and adoptive transfer of CD3+ T cells suppressed the progression of xenograft GC in vivo, with average tumor inhibition rates of 35.8–72.3% in vivo and 77.6%±4.7% in vitro (20). In addition, researchers have developed an engineered live bacterial near-infrared (NIR)-triggered system [H. pylori-Chlorin e6 (Ce6)]. In tumor-bearing mice, vaccination with this system resulted in an 80% survival rate at day 45 (21) (the principal mechanisms of action of GC vaccines are illustrated in Figure 1). Mechanisms of action of major therapeutic GC vaccines. DCs, dendritic cells; GC, gastric cancer; IFN, interferon; IL, interleukin; NK, natural killer; TNF, tumor necrosis factor. Recent advances in the development of H. pylori vaccines have led to substantial progress. Multi-epitope vaccines, DNA-based vaccines and formulations using Salmonella or Lactococcus as delivery vectors have elicited favorable immune responses (6). Notably, vaccines incorporating H. pylori antigens have also shown the potential to inhibit the growth of GC xenografts. Nevertheless, further studies are needed to optimize vaccine design and to enhance both immunogenicity and safety. Given the specific etiological association between H. pylori infection and gastric carcinogenesis, the development of H. pylori antigen-based vaccines to suppress GC progression may represent a novel and promising strategy for the prevention and treatment of GC in the future (22). Dendritic cell (DC) vaccine The primary function of DCs is to process and present TAAs to T lymphocytes. Moreover, DC vaccines loaded with allogeneic IgG and restricted by human leukocyte antigen (HLA) have been shown to exert potent antitumor effects in mouse models (23-25). DC vaccines exploit the strong antigen-presenting capacity of DCs to initiate and amplify host immune responses against tumor cells or infectious agents. In most clinical protocols, monocytes are first isolated from peripheral blood and differentiated ex vivo into DCs using defined cytokine cocktails. These DCs are then loaded with TAAs and induced to fully mature through additional cytokine stimulation. After being reinfused into the patient, the antigen-pulsed DCs traffic to secondary lymphoid organs, including lymph nodes, where they prime and expand antigen-specific T-cell populations, thereby promoting effective tumor cell killing or pathogen eradication (26,27). In a preclinical study, Bagheri et al. transfected DCs with total mRNA derived from spheroid-forming GC cells or from normal gastric tissue and used these DCs to prime T cells. T cells stimulated with DCs transfected with spheroid cell mRNA exhibited a marked increase in IFN-γ mRNA expression, with a 6.4- to 9.39-fold upregulation. The cytotoxic activity of T lymphocytes was also significantly higher than that of the other groups (P≤0.0001) (28). Mao et al. designed an in situ DC vaccine platform, NLC/Ce6. In tumor-bearing mice, NLC/Ce6 treatment markedly suppressed both primary and distant tumors (primary tumor volume, 223 mm3; distant tumor volume, 81 mm3) compared with controls (796 mm3 and 522 mm3, respectively). These data indicate that this in situ DC vaccine strategy can effectively control primary gastric tumors and limit their distant metastatic growth in mice (29). Zhu et al. developed a DC-based vaccine targeting MG-7Ag, a GC-associated antigen. This vaccine elicited a robust cytotoxic T lymphocyte (CTL) response. In vivo, adoptive transfer of CTLs primed by the MG-7Ag DC vaccine markedly suppressed xenograft tumor growth in nude mice, reducing tumor volumes to approximately one-third of those in animals receiving a conventional DC vaccine (30). DC vaccines remain a dynamic and rapidly evolving area of GC immunotherapy. However, further refinement of vaccine design is needed to enhance immunogenicity while maintaining an acceptable safety profile. Recently explored complementary strategies include next-generation adjuvants to boost DC activation, chemical modulation to improve antigen uptake, loading DCs with tumor cell lysates, and generating DC-T-cell conjugates or fusion hybrids (31-34). As these technologies are translated and adapted to GC, DC vaccines are expected to play an increasingly important role in the overall strategy of GC vaccination and immunotherapy. Nucleic acid vaccines Nucleic acid vaccines constitute a novel vaccine platform that harnesses the host cell’s intrinsic transcriptional and translational machinery to synthesize target antigens, thereby mimicking the natural processes of antigen expression and presentation that occur during viral or other pathogenic infections. This strategy is designed to elicit robust humoral and cellular immune responses. In addition, nucleic acid vaccines possess the advantages of flexible design, rapid development, a favorable safety profile, strong immunogenicity, easy large-scale production, and cost-effective manufacturing (35,36). Over the past three decades, studies have established the feasibility of direct in vivo transfection of mammalian cells using naked plasmid DNA (37,38). In this context, Afkhamipour et al. engineered a recombinant plasmid encoding the H. pylori urease accessory protein F gene (ureF) gene and used it to immunize BALB/c mice. This DNA vaccine achieved in vivo tumor inhibition rates of 35.8–72.3% and an in vitro inhibition rate of 77.6%±4.7%, underscoring its antitumor potential (39). mRNA vaccines have emerged as a powerful alternative to conventional vaccine platforms, offering high efficacy, good safety profile and the capacity for rapid and cost-efficient large-scale manufacturing (40). Wei et al. identified RAI14 and NREP as candidate TAAs that may be suitable targets for gastric adenocarcinoma (GAC)-directed mRNA vaccine development (41). You et al. identified ADAMTS18, COL10A1, PPEF1, and STRA6 as additional potential mRNA vaccine antigens for GAC (42). In a mouse experiment, researchers evaluated the efficacy of a neoantigen-mRNA lipid nanoparticles (LNPs) in combination with anti-programmed cell death protein 1 (PD-1) therapy in a mouse peritoneal metastasis model, and found that it exhibited beneficial activity in both the prevention and treatment of GC peritoneal metastasis in mice (43). Traditionally, mRNA vaccines adopt a linear mRNA or self-amplifying mRNA (SAM) design (44). Subsequently, to extend the expression duration and stability of mRNA, circular mRNA (circ-RNA) vaccines have been further developed (45). At present, mRNA vaccines lack more effective vaccine design strategies. Tumor Open Reading Frames that are Unique mRNA (TOFU mRNA) is a novel linear mRNA vaccine design method, which can load multiple tumor-specific antigens, making mRNA vaccines a promising personalized vaccine (46). Combining circ-RNA profiling analysis with pharmacogenomic approaches helps optimize treatment models, overcome drug resistance, and ultimately improve patient prognosis (47). In addition, appropriate mRNA structural modifications (such as codon optimization, nucleoside modification, SAM, etc.) and formulation methods (such as LNPs, polymers, peptides, etc.) are also promising solutions (36). Peptide-based vaccines Peptide-based cancer vaccines aim to elicit effector adaptive immune responses and to establish durable, antigen-specific immunity against tumor antigens recognized as non-self (48). Within this context, Wiedermann and colleagues developed a peptide-based B-cell epitope vaccine, IMU-131 (HER-Vaxx), and evaluated it in a clinical trial enrolling 14 patients with human epidermal growth factor receptor 2 (HER2)-overexpressing tumors. The treatment yielded one complete remission (CR), five partial remissions (PR), four cases of stable disease (SD) and one case of progressive disease (PD), indicating that IMU-131/HER-Vaxx is generally well tolerated and has an acceptable safety profile in patients with GC (49). Peptide-based vaccines offer several advantages, including a precisely defined composition, a generally favorable safety profile and a low frequency of severe adverse events. However, their broader clinical application is limited by the difficulty of identifying peptide epitopes that are both highly immunogenic and selectively expressed in tumor tissue. OTSGC-A24 is an HLA-A*24:02-restricted multipeptide vaccine. In a phase I/Ib study by Sundar et al., patients treated with OTSGC-A24 achieved a median progression-free survival (mPFS) of 1.7 months (95% CI: 1.4–3.5) and a mOS of 5.7 months (95% CI: 3.8–8.6) (50). In a separate trial, Fujiwara et al. evaluated an HLA-A*24-restricted peptide cocktail plus an anti-angiogenic peptide targeting VEGFR1 in 35 patients with unresectable or recurrent GC that had progressed after standard chemotherapy. The median survival time (MST) was 155 days. Among evaluable patients, 10 (45%) achieved SD, whereas 12 (55%) had PD (51). Wang et al. developed a peptide vaccine platform: T7-MG3. In BALB/c mice, vaccination with T7-MG3 significantly reduced tumor burden to 62.64%±5.55% of that in PBS-treated controls (P<0.01). Moreover, this vaccine enhanced CTL cytotoxicity (40.92%±4.38% vs. 16.29%±1.90%; P<0.01) (52). In another study, Jiang et al. used cryo-ultrasonic fragmentation to isolate GC stem cells and then prepared chaperone molecule-antigen peptide complexes derived from these cells. The resulting complexes showed strong immunogenicity and exhibited antitumor activity in vitro, highlighting their potential as immunotherapeutic candidates (53). Peptide vaccines have multiple advantages, including precisely defined molecular composition, good safety with extremely low toxicity, ease of chemical synthesis, and the ability to elicit potent antigen-specific immune responses. Despite these advantages, clinical development remains constrained by the challenge of identifying epitopes that are both highly immunogenic and selectively expressed in tumors. With continued advances in tumor antigen discovery and epitope prediction, next-generation peptide vaccines incorporating novel targets may hold considerable promise for clinical translation. Nanovaccines Nanovaccines are a new generation of immunization agents that use nanoparticle (NP)-based carriers and/or adjuvants. They offer several advantages, including enhanced drainage to lymphoid organs, co-delivery of multiple antigens and immunostimulatory molecules, and the ability to elicit sustained antitumor immunity (54,55). Liposomal and lipoprotein-like nanovaccines exhibit excellent biocompatibility, enable facile surface modification with targeting moieties, protect antigens from enzymatic degradation in vivo, and prolong antigen retention (56). Huang et al. developed the HPPS@RMn nanovaccine. In mice, tumor growth in the treatment group was significantly slower than in control groups, and final tumor volumes were markedly reduced. This effect was accompanied by a significantly higher proportion of CD44+CD62L+ central memory T cells among total CD8+ T cells (57). PLGA polymer nanovaccines are based on poly(lactic-co-glycolic acid) (PLGA), a material with excellent biocompatibility, complete biodegradability, and minimal apparent toxicity. They also enable prolonged antigen delivery and extended immune stimulation (58). In one study, PLGA NPs were used as delivery vehicles. After treatment, the ability of the treatment group to promote T cells to secrete IFN-γ was more than twice that of the control group, the tumor volume and weight were significantly smaller than those in other control groups, and the MST of tumor-bearing mice was significantly prolonged (59). Chitosan-based nanovaccines exhibit good biocompatibility, low toxicity, and degradability. They have pH responsiveness and can achieve targeted release of antigens under the acidic conditions of the tumor microenvironment (TME). In addition, chitosan itself can serve as a weak immune adjuvant (60). Researchers developed a NIR light-responsive chitosan-based nanovaccine, which showed excellent antiproliferative effects in HGC-27 and AGS cell models (IC50 =0.096 µm for HGC-27 cells) and exhibited extremely good biocompatibility with normal cells (cell viability above 88.7%) (61). Hydrogel nanovaccines are often peptide-based hydrogels (e.g., RADA32). After injection, they can form an in vivo gel-like depot that enables sustained, localized release of antigens and adjuvants, thereby extending the duration of immune activation (62,63). Yu et al. reported a dynamic covalent hydrogel-based vaccine (DCHVax) that can recruit DCs in situ, promote DCs uptake and maturation of GC-specific antigens, elicit potent tumor-specific immune responses, and inhibit residual tumor growth after GC surgery (64). Metal-organic framework (MOF) nanovaccines enable efficient loading of antigens, chemotherapeutic agents, and immune adjuvants to support synergistic chemoimmunotherapy. MOFs can also degrade under the acidic conditions of the TME, allowing targeted release of encapsulated antigens and drugs (65). In an AGS human GC xenograft model, a copper-tetrahydroxybenzoquinone MOF nanovaccine (Cu-THBQ/AX) achieved a tumor inhibition rate of 81.2% and was reported to suppress tumor growth and distant metastasis (66). Self-assembled (carrier-free) nanovaccines are formed through the self-assembly of antigens with immune adjuvants via electrostatic and hydrophobic interactions. They enable efficient co-delivery of antigens and adjuvants and can support synchronized release (67). In one study, researchers prepared a self-assembled nanovaccine. This formulation was efficiently delivered to DCs, promoted DCs maturation, reduced regulatory T-cell (Treg) infiltration, and enhanced T-cell responses. When combined with anti-PD-1 therapy, it was reported to overcome gemcitabine resistance in GC and induce long-term immune memory (68). In addition to the aforementioned nanovaccines, biomimetic nanovaccines that utilize cell lysates, cell-derived nanovesicles, or extracted cell membranes as functional components have attracted extensive attention in the field (69). pH-responsive nanovaccines can release antigens at a specific pH, which helps improve the targeting of the vaccines (70). In addition, chiral nanomaterials are also have been proposed as candidates for the development of next-generation vaccines, relying on their unique optical, electronic, and catalytic properties (71). Personalized vaccines By analyzing tumor and matched normal tissues, accurately identifying tumor-specific neoantigens, and designing patient-specific vaccines, it is possible to elicit immune responses that selectively target cancer cells, thereby improving therapeutic efficacy (72). Although most personalized vaccines are still in the early stages of clinical development and face challenges such as high manufacturing costs and significant interpatient heterogeneity (73,74). However, with the advancement of science and technology, personalized vaccines are bound to become an important part of individualized treatment for GC. Liu et al. developed a personalized neoantigen nanovaccine platform (PNVAC) and initiated a phase I clinical trial. The results showed that patients vaccinated with this platform achieved 1-year and 2-year disease-free survival (DFS) rates of 96.6% (28/29) and 82.4% (14/17), respectively (75). Go et al. designed a nanovaccine, CCM-MPLA-aCD28. This formulation elicited a more potent immune response offering the induction of tumor-specific CD8+ T cells and demonstrated superior antitumor efficacy in tumor-bearing mice. These findings all demonstrate the potential and broad application prospects of personalized vaccines in the treatment of GC (34). Combination of vaccination with immune checkpoint inhibitors (ICIs) ICIs have rapidly emerged as transformative agents within the field of cancer immunotherapy, substantially reshaping treatment modalities of multiple tumor types (76,77). While therapeutic cancer vaccines prime antigen-specific immune responses, ICIs counteract tumor-induced immunosuppression. When used together, these modalities act synergistically to amplify immune activation, diversify effector responses, overcome immune evasion mechanisms and mitigate therapeutic resistance, ultimately contributing to improved patient outcomes (78). Guo et al. used a neoantigen-loaded monocyte-derived dendritic cell vaccine (Neo-MoDC) administered in combination with the anti-PD-1 antibody nivolumab. Imaging demonstrated a near-complete metabolic response on positron emission tomography (PET) at day 231 after the initial vaccination, and complete disappearance of ovarian implant metastases on computed tomography (CT) at day 389 of combination therapy. Follow-up indicated a sustained radiologic complete response lasting 25 months (as of October 2021) (79). The combined application of vaccines and ICIs has complementary advantages. However, there are relatively few relevant clinical studies. Future studies should expand the scope of clinical trials of combined treatment strategies to cover a broader population of GC patients with different disease stages and pathological subtypes, thereby achieving strict evaluation of efficacy, safety, and reproducibility. Vaccination combined with chemotherapy Chemotherapy remains a primary treatment modality for GC; however, despite its tumoricidal efficacy, substantial systemic toxicity often compromises patients’ quality of life. The combined application of GC vaccines and chemotherapy can enhance anti-tumor effects, reduce treatment-related toxicity, and improve patients’ quality of life (80). In a phase I study in Japan, 18 patients received dose-escalating cyclophosphamide 4 days before vaccination, followed by weekly administration of a five-peptide cocktail over a 4-week course. This regimen was associated with a mOS of 13.5 months, suggesting that low-dose cyclophosphamide may enhance the efficacy of multipeptide cancer vaccines (81) (the major clinical trials discussed in this review are summarized in Table 2). Table 2GC vaccines involved in clinical trialsTrial registration numberVaccine/vaccine combination therapyClinical stageTrial participant outcomeNCT02302170An oral recombinant Helicobacter pylori vaccineIII4,464 RR: 71.8%NCT02795988IMU-131/HER-VaxxIb14 11 pts: 1 CR, 5 PR, 4 SD, 1 PDNCT01227772OTSGC-A24I/Ib24 mPFS: 1.7 mo (95% CI: 1.4–3.5); mOS: 5.7 mo (95% CI: 3.8–8.6)UMIN000004389HLA-A24II35 SD: 10 pts (45%), PD: 12 pts (55%); MST: 155 daysChiCTR1800017319PNVACI30 1-yr OS rate: 96.6% (28/29); 2-yr OS rate: 82.4% (14/17)NCT03185429Neo-MoDC in conjunction with NivolumabI1 Radiologic complete tumor regression, sustained for 25 moNCT00676949Pentapeptide cancer vaccine combined with cyclophosphamideI18 OS: 13.5 moNCT01783951DC-CIK combined with S-1 plus cisplatinI19 1-yr OS rate: 87.5%; 1-yr PFS rate: 76.9%NCT02795988HER-Vaxx in combination with platinum-based chemotherapeutic agentsII36 mOS: 13.9 mo vs. chemotherapy-alone pts OS: 8.31 mo–gp96 vaccine combined with S-1/oxaliplatin (SOX)II73 2-yr OS rate: 81.9%CI, confidence interval; CR, complete response; GC, gastric cancer; mo, months; mOS, median overall survival; mPFS, median progression-free survival; MST, median survival time; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; pts, patients; RR, response rate; SD, stable disease; yr, year. GC vaccines involved in clinical trials CI, confidence interval; CR, complete response; GC, gastric cancer; mo, months; mOS, median overall survival; mPFS, median progression-free survival; MST, median survival time; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; pts, patients; RR, response rate; SD, stable disease; yr, year. Qiao et al. evaluated the therapeutic efficacy of combining dendritic cell-cytokine-induced killer cell therapy (DC-CIK) with S-1 (tegafur/gimeracil/oteracil potassium) and cisplatin in patients with advanced gastric cancer (AGC). A total of 63 patients were enrolled. The 1-year overall survival (OS) rate in the DC-CIK + S-1 + cisplatin group was 87.5%, the 1-year progression-free survival (PFS) rate in the DC-CIK + S-1 + cisplatin group (76.9%) (82). Zhang et al. conducted a phase II trial to evaluate the safety and efficacy of adjuvant vaccination with gp96, an autologous heat shock protein derived from tumor tissue, in patients with GC. Thirty-eight patients received gp96 vaccination concurrently with chemotherapy. The gp96 group had improved DFS compared with chemotherapy alone (P=0.045; HR =0.47; 95% CI: 0.23–0.96). The 2-year OS rates were 81.9% in the gp96 group (P=0.123; HR =0.42; 95% CI: 0.15–1.24) (83). Although combining GC vaccines with chemotherapy shows promise for prolonging survival and improving quality of life, the clinical evidence remains limited and largely preliminary. Further studies are needed to define optimal vaccine-chemotherapy pairings, determine appropriate sequencing, and identify patient subsets most likely to benefit from multimodal approaches. Such insights will provide a scientific basis for refining combination regimens and guiding the design of next-generation GC vaccines. Overcoming the immunosuppressive TME In clinical practice, even when tumor vaccines generate detectable T-cell responses, robust antitumor efficacy is often difficult to achieve, largely because of the immunosuppressive TME (84). The immunosuppressive TME comprises immunosuppressive cell populations, inhibitory cytokines, and other factors in the local milieu surrounding tumor cells. It limits immune-mediated tumor killing by impairing the infiltration, function, survival, and antigen recognition of tumor-reactive T cells, thereby undermining vaccine efficacy (85). Key mechanisms include the following: T cell infiltration disorder TME hinders T cells from crossing vascular and stromal barriers to reach the tumor parenchyma through three major mechanisms. First, abnormal tumor vasculature: tumor cells, tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs) secrete factors such as VEGF-A and ANGPT2, leading to endothelial disorganization and reduced expression of adhesion molecules (VCAM-1 and ICAM-1), thereby limiting T-cell extravasation (86,87). Second, stromal densification: CAFs deposit abundant extracellular matrix (ECM) components, including collagen and hyaluronic acid, creating a physical barrier that restricts T-cell migration (88,89). Third, chemokine imbalance: reduced levels of T-cell-recruiting chemokines (e.g., CXCL9 and CXCL10) and increased levels of chemokines associated with immune exclusion or suppression (e.g., CXCL12 and CCL22) diminish directional cues for T-cell trafficking (90-92). T cell dysfunction Immunosuppressive signals within the TME induce dysfunction or exhaustion in a subset of T cells. First, tumor and immune cells can overexpress ligands such as programmed death-ligand 1 (PD-L1) and galectin-9, which engage receptors including PD-1 and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) on T cells, suppressing proliferation and cytokine production and promoting T-cell exhaustion (93,94). Second, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), M2-polarized TAMs, and related subsets can impair T-cell function by secreting inhibitory mediators (e.g., IL-10 and TGF-β), competing for nutrients, and mediating contact-dependent suppression (95). Third, enrichment of inhibitory soluble factors [e.g., prostaglandin E2 (PGE2), adenosine, and VEGF] can directly dampen T-cell activation and support the expansion of immunosuppressive cells (96-98). Metabolic immunosuppression The Warburg effect in tumor cells contributes to a hypoxic, glucose-depleted, lactate-rich, and metabolically dysregulated TME. Hypoxia activates hypoxia-inducible factor 1α (HIF-1α) signaling, which suppresses T-cell activity and promotes apoptosis and exhaustion (99); the low-glucose environment results in insufficient energy supply for T cells, preventing their activation and proliferation (100,101). Finally, metabolic pathways such as IDO/TDO-mediated tryptophan catabolism to kynurenine and CD39/CD73-mediated adenosine production can inhibit T-cell function and promote apoptosis through nutrient depletion and accumulation of inhibitory metabolites (102,103). Tumor immune escape Under vaccine-driven immune selection pressure, tumor cells may evade T-cell recognition via antigen gene silencing, deletion, mutation, or antigen modulation (104). In addition, immunosuppressive cells such as TAMs and MDSCs secrete inhibitory cytokines (e.g., IL-10 and TGF-β). These factors interfere with the maturation and differentiation of DCs, ultimately impairing efficient T-cell recognition and promoting immune escape (95,105,106). In addition to the immunosuppressive TME, microbial community structure and metabolites influence DCs maturation and antigen presentation, as well as T- and B-cell function. This may contribute to suboptimal vaccine efficacy in some patients (107,108). To overcome these obstacles, multiple strategies can be adopted. Combining vaccines with metabolic modulators (e.g., butyrate and IDO1 inhibitors) may alleviate metabolic deprivation, enhance CTL effector function, and promote vascular normalization, thereby improving T-cell metabolism and intratumoral infiltration (109-112). In addition, combining microbiome-based interventions with tumor vaccines may improve antigen presentation and tumor immunogenicity by remodeling the gut-tumor immune axis (113-115). Finally, vascular normalization strategies (e.g., targeting ANGPT2/TIE2 or dual blockade of VEGF and ANGPT2) can restore vascular integrity and facilitate T-cell infiltration (116-119). Optimization of the development pipeline for GC vaccines Current screening strategies often prioritize candidates based on predicted HLA-binding affinity; however, ranking epitopes solely by binding affinity can yield substantial false-positive and false-negative results (120). By contrast, cancer vaccines based on whole-tumor lysates or neoepitopes have been reported to show higher major histocompatibility complex (MHC)-binding affinity (P<0.05) (121). These observations highlight the need to shift tumor vaccine antigen discovery from binding-centered screening toward function-oriented identification. First, effective vaccine design requires integrative optimization to bridge the proteogenomic gap between mRNA transcription levels and functional protein antigens (122,123). High-resolution phosphoproteomic studies have demonstrated that the biological relevance and therapeutic susceptibility of antigens are determined not only by static protein expression but also by their active signaling status (124-126). This is particularly important for aberrant post-translational modifications, which contribute to immune evasion, cell adhesion, and metastasis and also represent actionable vaccine targets that are often missed by purely genomic approaches (127,128). In addition, MHC II-restricted epitopes should be considered core components of vaccine design because they activate CD4+ T helper cells and synergize with CD8+ cytotoxic T cells primed by MHC I-restricted epitopes. This can help mitigate immune escape driven by loss of MHC I expression in some tumors (129,130). CD4+ T cells provide essential co-stimulatory signals for CD8+ cytotoxic T cells to enhance cellular immune efficacy (129), drive B cell activation and antibody maturation to improve humoral immunity, differentiate into effector subsets that directly mediate immune responses, and target tumor cell elimination (130). Notably, recent studies have reported that high CD4+ T-cell infiltration in GC tissue is associated with reduced 5-year postoperative survival and may serve as an independent adverse prognostic factor and an indirect indicator of benefit from immunotherapy (131), Together, these findings support incorporating MHC II-restricted epitopes as key elements in vaccine design. For vaccine efficacy assessment, the proportions of PD-1-positive CD4+ T-cell subsets in peripheral blood have been reported to predict response rate, PFS, and OS in patients with advanced GC receiving combination chemoimmunotherapy, supporting their use as noninvasive biomarkers for patient selection (132). High intratumoral density of CD4+ tumor-infiltrating lymphocytes (TILs) has been identified as an independent risk factor for shorter OS and, together with high PD-L1 expression and increased CD163+ TAM infiltration, is associated with poor prognosis. By contrast, high CD8+ TIL infiltration predicts favorable outcomes, and combined assessment of these features may improve stratification of GC patients for immunotherapy benefit (133). Recently, advanced artificial intelligence (AI) models such as IEPAPI and TLimmuno2 have been used to predict MHC I and II immunogenicity by integrating peptide-HLA binding with T-cell receptor (TCR) recognition patterns, addressing the traditional emphasis on CD8+ T-cell epitopes alone (134,135). Current studies have not fully accounted for tumor heterogeneity and molecular subtype characteristics when discussing vaccine efficacy. High-resolution proteomic and phosphoproteomic studies have demonstrated that the definition of clinically relevant tumor subtypes (such as immune-inflammatory, metabolism-dominant, or mesenchymal GC) depends not only on genomic alterations but also on active signaling states (136-138). Among these, phosphorylation-driven status directly impacts antigen presentation capacity, immune cell infiltration patterns, and sensitivity to immunotherapy (139). Therefore, vaccine efficacy should be evaluated based on tumor subtypes defined by phosphoproteomics, rather than treating GC as a single disease. Notably, integrated signaling pathway analysis can identify functionally essential antigens—antigens that are not only overexpressed but also directly drive tumor progression, thus holding higher priority. Integrin αv (CD51), β5 (ITGB5), and others have been validated as functionally essential antigens in GC (140-142). In addition, studies have reported that GC patients with higher TCR repertoire diversity exhibit more durable vaccine-induced antigen-specific T-cell responses and improved 5-year survival compared with those with lower diversity (143). Recent deep learning-based frameworks, such as BertTCR and THLANet, enable systematic characterization of TCR repertoire features associated with clinical response, moving beyond simple T-cell counts to assess the functional fitness of adaptive immunity (144,145). Predicting neoantigen immunogenicity should incorporate peptide-HLA-TCR ternary complex modeling rather than relying solely on HLA-binding predictions. This concept is supported by advanced AI methods that integrate structural and sequence information, such as NeoaPred and THLANet (145,146). Tertiary lymphoid structures (TLSs) are organized ectopic lymphoid aggregates within the TME and have been associated with improved prognosis and enhanced responses to immunotherapy, particularly immune checkpoint blockade (147). Spatial characterization of TLSs may provide biomarkers for predicting and monitoring vaccine responses. For example, Wang et al. performed integrated single-cell and spatial transcriptomic analyses of 30 GC specimens and demonstrated the predictive value of TLS features for immunotherapy outcomes in GC (148). The key to the future of GC vaccine development lies in population-scale validation. National whole-genome sequencing projects and multi-omics biobank resources have laid an important foundation for subtype-specific patient screening, target validation across genetic backgrounds, and scalable clinical trial design (149). This is particularly important for East Asian populations—its molecular characteristics also differ significantly from those of Western populations. Based on this, the development of GC vaccines should first distinguish between broadly applicable targets and population-specific targets. For example, TP53 is a core broad-spectrum target for GC, while CLDN18.2 is an East Asian-specific target, with a positive expression rate of 42% in East Asians compared to only 21% in Westerners (P<0.001) (150). For example, copy number deletions of FAT4 and ZFHX4 genes are only associated with peritoneal metastasis in East Asian GC patients [hazard ratio (HR) =2.3, P<0.01] (151). The cost of tumor vaccines has greatly limited their clinical application scale; therefore, vaccine cost should be included in the evaluation of vaccine efficacy before large-scale population validation. The integration of cost-effective production platforms such as plant-derived recombinant protein systems may become an effective way to achieve equitable access to vaccines in high-burden, resource-limited regions (152,153). Evaluation of AI‑based epitope prediction tools AI-based epitope prediction tools have enabled high-throughput screening with improved accuracy by leveraging deep learning, multi-omics integration, and structural modeling. For example, models such as MUNIS and GraphBepi can capture sequence and structural features of peptide-HLA-TCR ternary complexes, thereby improving the identification of T- and B-cell epitopes and tumor neoantigens (154,155). Despite these advances, important limitations remain, including population and disease biases in training datasets; incomplete modeling of tumor heterogeneity and the immune microenvironment; discordance between in vitro predictions and in vivo immune responses; reduced performance for low-frequency mutant epitopes and conformational epitopes; and inflated false-positive rates due to a paucity of high-quality negative validation data (146,156,157). These constraints hinder clinical translation. Accordingly, the effective use of AI epitope prediction tools requires an integrated framework that couples algorithm refinement with multidimensional experimental validation and clinical calibration. Incorporating population-specific datasets, improving interpretability, and combining in vitro assays (e.g., ELISpot and pMHC tetramer staining) with in vivo animal models may strengthen the link between computational predictions, experimental immunology, and clinical outcomes, thereby maximizing translational utility (146,158). Before epitopes identified by AI can be advanced into clinical vaccine trials, the minimum required validation includes: in silico verification (MHC binding, antigen processing and presentation, population HLA coverage, conservation/safety), in vitro functional validation [peptide-MHC binding, confirmation of presentation by immunopeptidomics, detection of specific T-cell responses by ELISPOT/flow-based activation‑induced marker assay (AIM) assays], and in vivo validation in humanized animals (induction of functional immunity, preliminary protection/safety). Only upon establishing a closed-loop evidence chain from prediction to function can clinical applications be submitted (159,160). Conclusions Different types of GC vaccines exhibit varying degrees of antitumor potential. Among them, H. pylori vaccines provide an important direction for GC prevention, while personalized vaccines, nanovaccines, and combination therapeutic strategies have significantly enhanced the clinical application value of vaccines. Although AI-based epitope prediction tools have achieved high-throughput and high-precision breakthroughs in epitope screening, they still have limitations such as data bias and insufficient modeling of biological complexity, necessitating integration with in vitro validation and in vivo animal model verification. Furthermore, as a high-risk population for GC, East Asian populations possess unique molecular characteristics that require vaccine development to distinguish between broad-spectrum and population-specific targets. Overall, considerable room for optimization remains in GC vaccine research and development. In the future, with further advances in immunology, molecular biology, and AI technologies, as well as the implementation of large-scale population validation and low-cost production techniques, personalized vaccines and precise combination therapeutic strategies will continue to promote the clinical translation of GC immunoprophylaxis and treatment, bringing new breakthroughs for improving the prognosis of GC patients. Supplementary The article’s supplementary files as Acknowledgments We would like to express our sincere gratitude to all those who offered valuable guidance during the writing of this review. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-aw-2299/rc Funding: This project is supported by the National Natural Science Foundation of China (grant No. 82203267), the Gansu Health and Health Industry Research Project (No. GSWSKY2024-06), and the Cuiying Scientific and Technological Innovation Project of the Second Hospital of Lanzhou University (No. CY2024-MS-B18). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-aw-2299/coif). The authors have no conflicts of interest to declare. References Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-aw-2299/prf Supplementary Materials The article’s supplementary files as